NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Ethan Korngold: I’m Excited by The New CREST-2 Trial Data Presented at SVIN2025, VEITH2025 and Published in NEJM
Ethan Korngold/LinkedIn
Nov 23, 2025, 10:12

Ethan Korngold: I’m Excited by The New CREST-2 Trial Data Presented at SVIN2025, VEITH2025 and Published in NEJM

Ethan Korngold, Chief Medical Officer and DVP of Medical Affairs for the Abbott Vascular Business Unit, shared on LinkedIn:

”I’m excited by the new CREST-2 trial data presented at SVIN2025, VEITH2025 and published in NEJM adding an important chapter to understanding stroke prevention in patients with high-grade asymptomatic carotid stenosis.

In the stenting trial, carotid artery stenting (CAS) added to intensive medical therapy was associated with 2.8% stroke and death out to 4-years vs 6.0% for medical therapy.

The absolute difference of 3.2% favoring CAS was significant.

We are proud of the role our market leading carotid technologies including Xact and Emboshield NAV6, have in advancing research in stroke prevention.

These results will encourage the field to re-examine long-held assumptions about asymptomatic disease management.

As new evidence emerges, our responsibility is to interpret it carefully, understand where it applies, and continue refining strategies that support long-term patient outcomes.

My gratitude to the CREST-2 investigators for their commitment to a rigorous comparative study.

Read the abstract in NEJM.

Safety Info: Link 1; Link 2.”

Ethan Korngold: I’m Excited by The New CREST-2 Trial Data Presented at SVIN2025, VEITH2025 and Published in NEJM

Stay updated with Hemostasis Today.

Carotid Stenosis CREST-2 Emboshield NAV6 Ethan Korngold Health Hematology Hemostasis Hemostasis Today Medicine NEJM stroke prevention SVIN2025 thrombosis VEITH2025 Xact
NewsFeed